These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Early engraftment of G-CSF-primed allogeneic bone marrow transplantation in pediatric patients regardless of donor-recipient weight differences.
    Author: Kim H, Kang HJ, Lee JW, Park KD, Shin HY, Ahn HS.
    Journal: Ann Hematol; 2012 May; 91(5):751-758. PubMed ID: 22076065.
    Abstract:
    Harvesting sufficient progenitor cells from bone marrow (BM) for pediatric patients is a challenging process, especially from smaller donors. Growth factor administration to donors prior to harvest results in an enrichment of the graft and leads to early engraftment. A total of 41 patients received a human leukocyte antigen-identical sibling transplantation using granulocyte colony-stimulating factor (G-CSF)-primed BM. All donors received G-CSF 10 μg/kg/day for 2 days prior to harvest. The median weight difference between donor and recipient was 3.9 kg (range, -29.8 to 32 kg), and the median number of CD34(+) cells harvested was 4.16 × 10(6)/kg (range, 1.17-31.9 × 10(6)/kg). The median time to neutrophil engraftment was 12 days (range, 10-27 days), and the time for platelet engraftment was 20 days (range, 12-64 days). The cumulative incidence of acute grade 2 to 3 graft-versus-host disease (GVHD) and chronic GVHD was 4.9% and 5.1%, respectively. An analysis according to the weight difference between donor and recipient showed there was no significant difference in harvested CD34(+) cell dose and in time required for engraftment between smaller and heavier donor recipients. G-CSF-primed BM allows successful engraftment and provides a valuable alternative to unstimulated BM and peripheral blood stem cells with good engraftment and tolerable GVHD even in patients with smaller donors.
    [Abstract] [Full Text] [Related] [New Search]